promitil + capecitabine + bevacizumab

This is an **investigational combination therapy** consisting of: - **Promitil**: a liposomal prodrug of mitomycin-C, designed to enhance delivery to tumors and reduce systemic toxicity. Mechanistically, it acts as a DNA crosslinking agent after intracellular release of mitomycin-C, leading to cytotoxicity in tumor cells. - **Capecitabine**: an oral small molecule prodrug of 5-fluorouracil (5-FU), widely used in cancer therapy, especially in gastrointestinal cancers; it is metabolized in vivo to 5-FU, which inhibits thymidylate synthase and incorporation into RNA and DNA, leading to inhibition of tumor cell growth. - **Bevacizumab**: a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis required for tumor growth and metastasis. The combination aims to deliver coordinated cytotoxic and antiangiogenic effects, potentially enhancing clinical efficacy, particularly in cancers such as metastatic colorectal cancer.